Data center development is booming—driven by AI and other high-throughput workloads. But beyond the physical buildout, a new product is emerging that might enhance the sector’s value proposition: SLA insurance.
The capital intensity of data center projects attracts institutional investors. One common vehicle is asset-backed securitization, where data center leases and their associated cash flows are
Recent Developments
Recently Filed Complaints
Residential Mortgage Borrowers Allege Residential Mortgage Originators Exchange Sensitive Information and Fix Loan Prices – Mendez v. Optimal Blue, LLC, No. 25-cv-1140 (M.D. Tenn.)
D&O liability insurance policies protect “officers.” But who is an officer? This is a question that insurers and policyholders have struggled with for years. More recently, questions about various new corporate roles and titles have emerged. In the following guest post, John Orr, D&O Liability Product Leader for Willis’s Financial and Executive Risk
China Technology Licensing in 2025: A Practical Playbook for IP, Compliance, and Enforcement
Why this guide and why now
Licensing to Chinese companies is surging. In the first half of this year, our law firm handled more China licensing agreements than in any prior full year. Buyers in China want technology, brands, data, and know-how
In the following guest post, Sarah Abrams, Head of Claims Baleen Specialty, a division of Bowhead Specialty, takes a look at California’s recently enacted SB 53, state AI-related legislation concerning “large frontier developers,” and considers the legislation’s liability implications. I would like to thank Sarah for allowing me to publish her article
On October 1, 2025, Justice Cohen of the New York County Commercial Division issued a decision in Ader v. Ader, 2025 NY Slip Op. 51563(U), sanctioning a lawyer for poorly-checked use of AI in generating papers, explaining:
This case adds yet another unfortunate chapter to the story of artificial intelligence misuse in the legal
Background
Artificial Intelligence (“AI”) has been utilized by innovative companies across the array of industry spaces, but its impact on biotech (and human health in general) could become the most significant among all sectors.
AI is being leveraged across the drug development spectrum to accelerate inherently burdensome tasks including the identification of targets and leads,
On September 2, 2025, U.S. Representative Zachary Nunn sent a letter to the chair of the Committee on Foreign Investment in the United States (CFIUS) highlighting concerns over ownership transparency of certain bitcoin mining firms and suppliers connected to China. The national security attention on bitcoin mining supply chains reveals why corporate boards and their
On June 10, 2025, the U.S. Courts’ Committee on Rules of Practice and Procedure approved a set of proposed amendments to the Federal Rules, including introducing Proposed Federal Rule of Evidence 707, which addresses the admissibility of AI-generated evidence. Proposed Rule 707 would require that machine-generated evidence—when offered without a human expert—meet the same admissibility
Generative AI is rapidly becoming a go-to tool for efficiency across many industries, but its unchecked use in the legal field is setting a dangerous precedent. We’ve seen trial lawyers get caught using AI that “hallucinates” and creates fake case citations. Now, even federal judges are under scrutiny for allegedly using AI to draft error-ridden